home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505a.zip
/
M9550151.TXT
< prev
next >
Wrap
Text File
|
1995-03-04
|
3KB
|
41 lines
Document 0151
DOCN M9550151
TI Pharmacokinetics of HIV protease inhibitor DMP 323 in rats and dogs.
DT 9505
AU Grubb MF; Wong YN; Burcham DL; Saxton PL; Quon CY; Huang SM; Drug
Metabolism and Pharmacokinetics Section, DuPont Merck; Pharmaceutical
Company.
SO Drug Metab Dispos. 1994 Sep-Oct;22(5):709-12. Unique Identifier :
AIDSLINE MED/95136855
AB DMP 323 is a symmetrically substituted cyclic urea compound with
demonstrated activity against human immunodeficiency virus (HIV) in
vitro. DMP 323 has been measured in rat and dog plasma via liquid-liquid
extraction and HPLC. The limit of quantitation is 10 ng/ml using 0.5 ml
plasma. Following an intravenous dose of 5 mg/kg to rats, DMP 323
exhibited an apparent volume of distribution at steady-state of 6.36
liters/kg and clearance of 7.12 liters/hr/kg. The same dose administered
intravenously to dogs resulted in apparent volume of distribution at
steady-state and clearance values of 2.28 liters/kg and 1.48
liters/hr/kg, respectively. Elimination half-lives were 0.95 hr in rats
and 1.80 hr in dogs. DMP 323 was rapidly absorbed from oral solution
doses in rats (3, 5, and 10 mg/kg) and dogs (5 and 10 mg/kg), achieving
maximum plasma concentrations in 1 hr or less in both species. Absolute
bioavailability of DMP 323 from oral doses ranged from 15 to 27% in rats
and from 37 to 38% in dogs. Pharmacokinetics were unchanged in rats and
dogs over 8-day t.i.d. and 5-day b.i.d. multiple oral dose regimens,
respectively. Oral doses administered to fed animals resulted in lower
plasma concentrations of DMP 323 than the same doses administered to
fasted animals. Because of its in vitro high potency and acceptable
pharmacokinetics, DMP 323 seems to be a worthy candidate for further
study in the effort to develop an inhibitor of HIV protease for use in
the therapy of AIDS.
DE Administration, Oral Animal Biological Availability Comparative Study
Dogs Half-Life HIV Protease Inhibitors/BLOOD/*PHARMACOKINETICS
Injections, Intravenous Male Rats Rats, Sprague-Dawley Species
Specificity Urea/*ANALOGS & DERIVATIVES/BLOOD/PHARMACOKINETICS JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).